Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus CORDRAN SP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus CORDRAN SP.
ARAZLO vs CORDRAN SP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), inhibiting arachidonic acid release and subsequent prostaglandin and leukotriene synthesis, thereby mediating anti-inflammatory, antipruritic, and vasoconstrictive effects.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Apply a thin film to the affected area 1 to 2 times daily. Use the smallest amount for adequate therapy. Do not use for more than 2 weeks per course of treatment.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Terminal half-life approximately 48 hours; prolonged with hepatic impairment.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Primarily renal as inactive metabolites; <5% unchanged. Minimal biliary/fecal elimination.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid